Biology

Nobilis Therapeutics Announces IND Filing for a Phase 2b Clinical Trial of NBTX-001 Drug/Device Combination for Treatment of Panic Disorder



PORTLAND, Ore. (PRWEB) June 23, 2020 Nobilis Therapeutics, a biopharmaceutical company focused on the advancement of innovative CNS therapies, today announced that it has filed an Investigational New Drug application (IND) with the U.S. Food & Drug Administration (FDA) to initiate a Phase…

Source link

Related posts

Polarized light sensitivity in Pieris rapae is dependent on both color and intensity [RESEARCH ARTICLE]

Newsemia

Macrophages as Both Friends and Foes in Age-Related Diseases

Newsemia

Heat Shock Proteins Support Refolding and Shredding of Misfolded Proteins

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World